Full text
Earnings transcript
Read the complete earnings call transcript.
RMD
ResMed Inc.
$238.97
-3.26
(-1.35%)
| Exchange: | NYSE |
| Market Cap: | 33.609B |
| Shares Outstanding: | 48M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Medical – Instruments & SuppliesView industry performance | |||||
| CEO: | Michael J. Farrell | |||||
| Full Time Employees: | 11370 | |||||
| Address: |
| |||||
| Website: | https://www.resmed.com |
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company’s headquarters are located in San Diego, California.
Click to read more…
Revenue Segmentation
RMD full analysis
Welcome to MARKETSNAP’s SWOT analysis for ResMed, a heavyweight in the medical equipment space. If you’re a long-term investor looking to dig into a company that’s making waves in healthcare, you’ve come to the right place. Today, we’re breaking down ResMed—known for its innovative solutions in sleep apnea and respiratory care—through a detailed SWOT analysis. We’ll cover their strengths, weaknesses, opportunities, and threats, while weaving in the latest financials, news, and insights to help you gauge whether this stock fits…
Industry Peers
| TICKER | COMPANY | MKT CAP | P/E | FWD P/E | ROIC |
|---|---|---|---|---|---|
| RMD | ResMed Inc. | 33.6B | 22.0 | 21.5 | 19.1% |
 MDLN | Medline Inc. | 31.5B | 42.2 | 24.1 | 4.0% |
 WST | West Pharmaceutical Services, Inc. | 27.0B | 46.5 | 42.8 | 15.8% |
 BDX | Becton, Dickinson and Company | 52.2B | 55.3 | 15.1 | 3.7% |
 SOLV | Solventum Corporation | 14.6B | 10.6 | 12.0 | 15.9% |
 BAX | Baxter International Inc. | 13.1B | — | 12.3 | -1.6% |
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 4,685,297 | 5,146,327 | 5,653,443 |
| Gross Profit | 2,655,303 | 3,054,970 | 3,451,739 |
| EBITDA | 1,533,543 | 1,913,377 | 2,152,612 |
| Operating Income | 1,319,893 | 1,685,363 | 1,908,460 |
| Net Income | 1,020,951 | 1,400,723 | 1,523,293 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Total Assets | 6,872,394 | 8,174,391 | 8,965,950 |
| Total Liabilities | 2,008,351 | 2,206,532 | 2,380,557 |
| Total Stockholders Equity | 4,864,043 | 5,967,859 | 6,585,393 |
| Total Debt | 873,935 | 882,319 | 825,919 |
| Cash and Cash Equivalents | 238,361 | 1,209,450 | 1,469,234 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating Cash Flow | 1,401,260 | 1,751,588 | 1,805,829 |
| Capital Expenditure | -114,856 | -89,865 | -156,285 |
| Free Cash Flow | 1,286,404 | 1,661,723 | 1,649,544 |
| Net Income | 1,020,951 | 1,400,723 | 1,523,293 |
| Net Change in Cash | 10,470 | 971,089 | 259,784 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 6,980,519.320 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 7,197,983.132 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 7,064,058.582 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 2,975,938.532 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 3,087,499.875 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 3,018,795.676 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 2,229,878.770 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 2,320,511.967 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 2,264,696.207 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 1,396,021.906 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 1,439,512.115 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 1,412,728.777 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 15.620 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 16.010 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 15.380 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 4 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 5 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: ResMed reported strong financial results in Q4 FY2025, with key metrics such as revenue, net income, and operating cash flow showing positive trends as highlighted in the earnings call summary. This reflects effective operational management and market demand for its products.
- High Profitability Metrics: The company exhibits strong gross profit margin and net profit margin (TTM), indicating efficient cost control and profitability compared to industry peers in the healthcare equipment sector.
- Solid Cash Flow Generation: Free cash flow (TTM) and net cash provided by operating activities demonstrate ResMed’s ability to generate substantial cash, supporting reinvestment and debt management, as evidenced by cash flow statement data.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates RMD intrinsic value between $218.91 – $224.66 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about RMD valuation
Is ResMed Inc. (RMD) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for ResMed Inc. (RMD) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is RMD a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether RMD trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is RMD’s P/E ratio?
You can see RMD’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for RMD?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is RMD a good long-term investment?
Whether RMD fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
RMD
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-1.35
Trading Metrics:
| Open: | 241.02 | Previous Close: | 242.23 | |
| Day Low: | 237.96 | Day High: | 242.58 | |
| Year Low: | 180.27 | Year High: | 277.67 | |
| Price Avg 50: | 226.66 | Price Avg 200: | 225.05 | |
| Volume: | 2.522M | Average Volume: | 1.394M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
